Controlling the Global Epidemic. How are Weight-Loss Drugs Shifting the Obesity Saga? 2023: Translation to Practice®

This session will provide an in-depth overview of medications for obesity. Participants will learn about the different types of medications available, their mechanisms of action, and the potential benefits and limitations of using medication as a weight loss intervention. The session will also cover the criteria for patient selection, including BMI, comorbidities, and medication contraindications, as well as the potential side effects and safety considerations of obesity medications. The session will also explore the effectiveness of obesity medications in achieving weight loss and improving health outcomes, as well as the role of healthcare providers in prescribing and monitoring medication therapy. Strategies for patient education and follow-up will be discussed, as well as the importance of a comprehensive weight management approach that includes lifestyle modifications, behavior change, and support.

Course summary
Available credit: 
  • 2.00 AAFP Prescribed
  • 2.00 AMA PRA Category 1 Credit™
Course opens: 
Course expires: 

Learners can earn up to 2 AAFP Prescribed credits for participation in EACH Translation to Practice® (t2p) survey from 2023 Family Medicine POP.

The AAFP has reviewed 2023 Family Medicine POP! and deemed it acceptable for AAFP credit. Term of approval is from 8/25/2023 to 8/27/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Available Credit

  • 2.00 AAFP Prescribed
  • 2.00 AMA PRA Category 1 Credit™
Please login or register to take this course.